PFF Summit 2013 Professional Sessions

Professional Sessions

FRIDAY > SCIENTIFIC SESSIONS

Welcome and Introduction

Daniel M. Rose, MD, CEO and Chairman of the Board, Pulmonary Fibrosis Foundation | VIEW SLIDES | WATCH WEBINAR

Opening Session Keynote Address

Cystic Fibrosis Therapeutic Development: A Game Changer,  Robert J. Beall, PhD, President and CEO and Chairman of the Board, Cystic Fibrosis Foundation | VIEW SLIDES | WATCH WEBINAR

Lung Injury and Repair

Leaders: Gregory P. Cosgrove, MD; Martin Kolb, MD, PhD; Patricia J. Sime, MD

Introduction: Lung Injury and Repair, Gregory P. Cosgrove, MD | VIEW SLIDES | WATCH WEBINAR

Targeting Matrix: Opportunities for Therapy, Patricia J. Sime, MD | VIEW SLIDES | WATCH WEBINAR

Role of Alveolar Epithelium in Pulmonary Fibrosis: Innocent Bystander or Active Participant?, Zea Borok, MD | VIEW SLIDES | WATCH WEBINAR

IPF Fibroblasts and Their Cell-of-Origin, Craig Henke, MD | VIEW SLIDES | WATCH WEBINAR

Cell Based Therapy to Correct the Tissue Milleu in IPF [Amniotic Fluid Stem Cell Therapy for the Treatment of Lung Disease], Orquidea Garcia, PhD for David Warburton, MD | VIEW SLIDES | WATCH WEBINAR

Special Luncheon Speaker

When Drug Research is Personal: The Importance of Patient Advocacy in Drug Development and Innovation, John F. Crowley, JD, MBA, Chairman and CEO, Amicus Therapeutics | WATCH WEBINAR

Personalized Medicine: Genetics and Biomarkers

Leader: Fernando J. Martinez, MD, MS

Introduction: Genetics and Biomarkers, Fernando J. Martinez

Genetic Markers: Impact on Outcome and Patient Management, Christine Kim Garcia, MD, PhD | VIEW SLIDES | WATCH WEBINAR

Genome-wide Approach to Personalized Survival in IPF, Imre Noth, MD | VIEW SLIDES | WATCH WEBINAR

Implementing Protein-based Biomarkers in IPF: Challenges and Future Directions, Ivan O. Rosas, MD |VIEW SLIDES | WATCH WEBINAR

Implications of Genetic Data, Janet Talbert, MS, CGC | VIEW SLIDES | WATCH WEBINAR

Drug Development in IPF (sessions not included in CME)

Leaders: A. Bruce Montgomery, MD; Dean Sheppard, MD

Introduction: Comparison of Regulatory Agencies and the Approval Process, A. Bruce Montgomery, MD | VIEW SLIDES | WATCH WEBINAR

Promising Therapeutic Targets, Dean Sheppard, MD | VIEW SLIDES | WATCH WEBINAR

Challenges of IPF Drug Development, Tom O'Riordan, MD | VIEW SLIDES | WATCH WEBINAR

SATURDAY  > CLINICAL SESSIONS

Leaders: Kevin R. Flaherty, MD, MS; Marvin I. Schwarz, MD; Jeffrey James Swigris, DO, MS; Leslie C. Watters, MD

Making an Accurate Diagnosis: How to Use the IPF Consensus Guidelines, Fernando J. Martinez, MD, MS |VIEW SLIDES | WATCH WEBINAR

Sleep Apnea and IPF: Coincidence or Causation?, David Lederer, MD, MS | VIEW SLIDES | WATCH WEBINAR

Pulmonary Hypertension in PF: To Test? To Treat?, Steven M. Kawut, MD, MS | VIEW SLIDES | WATCH WEBINAR

GERD and Microaspiration in PF: Fundoplication for Everyone?, Joyce Lee, MD |VIEW SLIDES | WATCH WEBINAR

Case Presentations with Master Clinicians |VIEW SLIDES | WATCH WEBINAR

Talking with PF Patients: Truth-telling while Maintaining Hope, Jeffrey James Swigris, DO, MS |VIEW SLIDES | WATCH WEBINAR

Patient and Pulmonologist Journey with IPF: A Breathtaking Experience, Craig S. Conoscenti, MD | VIEW SLIDES | WATCH WEBINAR

Existing and New Treatment Options: A Global Perspective

Non-Pharmacologic Treatment Options, Christopher J. Ryerson, MD | VIEW SLIDES | WATCH WEBINAR

Pirfenidone Treatment of IPF in the European Union, Carlo Vancheri, MD | VIEW SLIDES | WATCH WEBINAR

Future of Therapies and Clinical Trials, Kevin K. Brown, MD |VIEW SLIDES | WATCH WEBINAR

Clinical Trial Updates (sessions not included in CME)

Leader: Kevin K. Brown, MD

STX-100 (anti-αvβ6 mAb) in Patients with Idiopathic Pulmonary Fibrosis, Brad Maroni, MD, Biogen Idec |VIEW SLIDES | WATCH WEBINAR

Safety and Efficacy of A Lysophosphatidic Acid Receptor Antagonist (BMS 986020) in Idiopathic Pulmonary Fibrosis, Claudio Pasquinelli, MD, PhD, Bristol-Myers Squibb | VIEW SLIDES | WATCH WEBINAR

A Phase II Clinical Trial Evaluating JNK Inhibitor Tanzisertib (CC-930) in IPF, Gregory Ferguson, PhD, Celgene | VIEW SLIDES | WATCH WEBINAR

Treatment of Idiopathic Pulmonary Fibrosis with Anti-CTGF Monoclonal Antibody FG-3019: Interim Results of Phase 2 Clinical Trial,  John Stauffer, MD, FibroGen |VIEW SLIDES | WATCH WEBINAR

Overview of Lebrikizumab Program in Idiopathic Pulmonary Fibrosis (RIFF Study), Ari Gershman, DO, Genentech | VIEW SLIDES | WATCH WEBINAR

Protocol GS-US-322-0207: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER),  Thomas O’Riordan, MD, Gilead | VIEW SLIDES | WATCH WEBINAR

ImmuneWorks Lead Asset: IW001, David Wilkes, MD, ImmuneWorks | VIEW SLIDES | WATCH WEBINAR

Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) – the ASCEND Trial, Jonathan Leff, MD, InterMune | VIEW SLIDES | WATCH WEBINAR

An Adaptive, 2‑Staged, Randomized, Placebo‑controlled Study to Evaluate the Tolerability, Safety, and Efficacy of PRM‑151 in Patients with Idiopathic Pulmonary Fibrosis (IPF), Elizabeth Trehu, MD, Promedior | VIEW SLIDES | WATCH WEBINAR

Advocacy

Effective Advocacy for Pulmonary Fibrosis, Brain Baird, MS, PhD |VIEW SLIDES | WATCH WEBINAR

professionalsessions1

 

 

professionalsessions2

 

 

professionalsessions5

 

 

professionalsessions7
Exception occured while executing the controller. Check error logs for details. Exception occured while executing the controller. Check error logs for details.Exception occured while executing the controller. Check error logs for details.Exception occured while executing the controller. Check error logs for details.